NCNeihenuo Chuzho

Neihenuo Chuzho

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Neihenuo Chuzho has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Gunja Mishra

    Indian Council of Medical Research (ICMR)‐National Institute of Pathology Safdarjung Hospital Campus New Delhi India

    2 shared publications
  • Narinder K. Mehra

    Emeritus Scientist (ICMR), and Former Dean (Research) All India Institute of Medical Sciences New Delhi India

    2 shared publications
  • Neeraj Kumar

    ICMR-National Institute of Pathology, New Delhi, India

    2 shared publications
  • Akanksha Sharma

    Department of Transplant Immunology and Immunogenetics All India Institute of Medical Sciences New Delhi India

    1 shared publication
  • Gurvinder Kaur

    Laboratory Oncology Unit, Dr BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India

    1 shared publication
  • Neetu Mishra

    Symbiosis School of Biological Sciences Symbiosis International (Deemed University) Pune India

    1 shared publication

Latest Publications

  • Open Access

    HLA‐DR3 mediated CD4 T cell response against GAD65 in type 1 diabetes patients

    by Neihenuo Chuzho, Neetu Mishra, Nikhil Tandon, Uma Kanga, Gunja Mishra, Akanksha Sharma, Narinder K. Mehra, Neeraj Kumar

    Aim: We planned this study to identify diabetogenic glutamic acid decarboxylase (GAD65) peptides possibly responsible for human leucocyte antigen (HLA)‐DR3/DQ2‐mediated activation of GAD65‐specific CD4 T cells in type 1 diabetes (T1D).Methods: Top 30 GAD65 peptides, found to strongly bind in silico with HLA‐DR3/DQ2 molecules, were selected and grouped into four pools. The peptides were used to stimulate CD4 T cells of study subjects in 16‐h peripheral blood mononuclear cell culture. CD4 T cells' stimulation in terms of interferon‐gamma (IFN‐γ), interleukin (IL)‐17, tumor necrosis factor‐alpha (TNF‐α), and IL‐10 expression was analyzed using flow cytometry.Results: Although all four GAD65 peptide pools (PP1‐4) resulted in significantly higher expression of IFN‐γ by CD4 T cells (p = .003, p < .0001, p = .026, and p = .002, respectively), only pool 2 showed significant increase in IL‐17 expression (p < .0001) in T1D patients vs healthy controls. Interpeptide group comparison for immunogenicity revealed significantly higher IFN‐γ and IL‐17 expressions and significantly lower IL‐10 expression for PP2 compared to other groups (p < .0001, p = .02, and p = .04, respectively) in patients but not in controls. Further, group 2 peptides resulted in significant increase in CD4 T cells' expression of IFN‐γ and IL‐17 (p = .002 for both) and significant decrease in IL‐10 (p = .04) in HLA‐DRB1*03‐DQA1*05‐DQB1*02+ patients vs HLA‐DRB1*03‐DQA1*05‐DQB1*02+ controls. The CD4 T cells' expression of IL‐17 was significantly higher (p = .03) in recently diagnosed vs long‐standing HLA‐DRB1*03‐DQA1*05‐DQB1*02+ T1D patients.Conclusion: GAD65 peptides, particularly those belonging to PP2, induced CD4 T cells to express IFN‐γ and IL‐17 cytokines in T1D patients, suggesting that group 2 peptides possibly presented by HLA‐DR3 molecule to CD4 T cells shift immune balance toward inflammatory phenotype in patients.


  • Open Access

    Differential HLA Association of GAD65 and IA2 Autoantibodies in North Indian Type 1 Diabetes Patients

    by Neihenuo Chuzho, Neeraj Kumar, Neetu Mishra, Nikhil Tandon, Uma Kanga, Gurvinder Kaur, Paras Singh, Gunja Mishra, Shreya Sharma, Narinder K. Mehra

    The human leucocyte antigen (HLA) association with type 1 diabetes (T1D) is well known but there are limited studies investigating the association between β-cell autoantibodies and HLA genes. We evaluated the prevalence of GAD65 and IA-2 autoantibodies (GADA and IA2A) in 252 T1D patients from North India and investigated the genetic association of GADA and IA2A with HLA class I and class II genes/haplotypes. GADA and IA2A were detected in 50.79% and 15.87% of T1D patients, respectively, while only 8.73% had both GADA and IA2A. HLA-DRB103 was observed to be significantly higher in GADA+ T1D patients as compared to GADA– (91.41% vs. 66.13%, Bonferroni- ; ; 95% CI: 2.67-11.08). Similarly, HLA-DQB102 was found to be significantly increased in GADA+ patients (94.53%, ; ; 95% CI: 2.7-14.49) as compared to GADA– (73.39%). The frequencies of HLA-DRB104 and DQB103 were increased in IA2A+ patients (45.0% and 52.5%, respectively) as compared to that in IA2A– (25.94% and 33.96%, respectively). Further, the frequency of DRB103-DQB102 haplotype was found to be significantly increased in GADA+ T1D patients as compared to GADA- (60.55% vs. 41.94%, ; ; <use...